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Abstract
Background
A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not cur-
rently available.
Objectives
To assess the in vivo efficacy of a method to adjust the dose of enzymatic supplement in CF
extrapolated from previous in vitro digestion studies (theoretical optimal dose, TOD). Sec-
ondly, to assess how individual patient characteristics influence the expected coefficient of
fat absorption (CFA) and thus to identify an individual correction factor to improve TOD.
Methods
A prospective interventional study in 43 paediatric patients with CF from 5 European cen-
tres. They followed a 24h fixed diet with the theoretical optimal dose for each meal. Faecal
collection was carried out between colorimetric markers in order to include all the faeces cor-
responding to the fixed diet. Beta regression models were applied to assess the associa-
tions of individual patient characteristics with the CFA.
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Results
Median CFA was 90% (84, 94% 1st, 3rd Q.) with no significant differences among centres.
Intestinal transit time was positively associated with CFA (p = 0.007), but no statistical asso-
ciations were found with and age, gender, phenotype or BMI. Regression model showed no
improvement of the in vitro predicted theoretical optimal dose when taking individual patient
characteristics into account.
Conclusion
Strict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed
meal, led to median CFA levels at the clinical target of 90% with a low variability between
patients. The proposed method can be considered as a first approach for an evidence-
based method in PERT dosing based on food characteristics. Results have to be confirmed
in free dietary settings.
Introduction
Pancreatic insufficiency is associated with Cystic Fibrosis (CF) in up to 85–90% of the patients.
Pancreatic Enzyme Replacement Therapy (PERT) is the indicated treatment to compensate
for maldigestion and malabsorption of nutrients [1], and aims at maintaining or achieving an
adequate nutritional status. In the 80s, enteric-coated pancrelipase enzyme supplements were
applied in the clinical practice for the first time, showing an improvement in faecal fat losses as
compared to the conventional pancreatic enzymes [2,3]. This enteric-coated formulation
became from then onwards the standard treatment for PERT in CF. However, despite PERT,
fat absorption remains insufficient in most of the patients with CF, and the inaccuracy in the
dosing criterion has been suggested as a possible reason for this [4]. Over the last decades, sev-
eral studies have concluded that evidence-based guidance is needed to adjust the dose of enzy-
matic supplements given in PERT. However, to our knowledge, no successful attempt has
been made up to date [5–7].
Determination of fat in faeces and calculation of the coefficient of fat absorption (CFA)
have been used as the gold standard method to assess enzymatic supplement dosage efficacy
[6]. The CFA reflects the amount of fat excreted in faeces in relation to the dietary intake of fat.
Recently, an enormous variability in the response to doses used in PERT among patients has
been confirmed, with no clear association between CFA and the dose of the enzymatic supple-
ment [8,9]. Moreover, wide intra-and inter- patient ranges of the dose of enzymatic supple-
ment (LU/g fat) in a multicentre observational study were showed [10].
Recent research has identified the important influence of foods’ characteristics on the pro-
cess of lipolysis [7, 11–13]. Few investigations have considered integration of the specific food
characteristics of a wide range of foods to estimate the dose of the enzymatic supplement and
no trials have been performed to study this in vivo.
The main goal of the Horizon 2020 MyCyFAPP Project is to establish an evidence-based
method to identify the optimal dose of enzymatic supplements in CF, which will allow for
patients’ self-management of this therapy by means of a mobile app [14]. This project included
an in vitro digestion study of foods under standard CF simulated gastrointestinal conditions in
order to determine the theoretical optimal dose of enzymatic supplement (TOD) per food
product, based on food characteristics. In this study, the modelling of results confirmed that
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not only the amount of fat, but also the food characteristics–e.g. amount of other nutrients or
matrix properties–led to very significant variation in the doses of the enzymatic supplement
requirement for optimal digestion of food products with the same total amount of fat.
Next, the project aims to evaluate the efficacy of the TODs of the enzymatic supplement
when applied in vivo to patients. We hypothesized that an individual correction factor would
be identified for each patient to correct for individual patient characteristics (gender, age,
mutation type, transit time). Correction of the TOD by an individual correction factor may
result in the individual optimal dose, leading to the optimal dose of enzymatic supplement
needed to obtain an optimal CFA in vivo.
Therefore, the first aim of the present study was to assess the in vivo efficacy of an evidence-
based prediction model to adjust the dose of the enzymatic supplements used in PERT
obtained by means of an in vitro digestion experimental setting. Secondly, we aimed at identi-
fying an individual correction factor, based on individual patient characteristics, representing
the difference between the in vitro and in vivo scenarios. Therefore, in a prospective interven-
tional pilot study, we evaluated the variability in CFA between patients after consumption of a
predefined 24 hours diet in combination with the TOD of enzyme supplements, to identify
this individual correction factor.
Materials and methods
Subjects
Paediatric patients with CF followed up as outpatients in 5 European CF centres participating
in the MyCyFAPP project: Madrid (Spain), Valencia (Spain), Milan (Italy), Leuven (Belgium)
and Rotterdam (The Netherlands) were considered for enrolment.
Inclusion criteria required a confirmed diagnosis of CF (a documented sweat chloride� 60
mEq/L and a documented genotype with two disease-causing mutations in the CFTR gene),
age between 2 and 18 years, having pancreatic insufficiency (faecal elastase< 200 mcg/g fae-
ces), and need for treatment with PERT, having a stable clinical status at least two weeks before
signing the informed consent and patients’ having the capacity and willingness to fulfil the test
meals and the faeces collection. Patients were considered not stable to participate if they would
meet any of the exclusion criteria as explained below. CFA prior the inclusion in the study was
disregarded, as the aim was not to measure relative intra-patient improvement of this parame-
ter but to assess the CFA result achieved with the proposed dose optimisation method.
The exclusion criteria were the presence of an acute infection associated with decreased
appetite or fever at the time of the run-in visit, acute abdominal pain, severe liver disease in the
assumption that in a few patients it may be associated with a certain degree of cholestasis,
FEV1 <40% predicted, severe hypoalbuminemia (<2.5g/ml in blood), hospitalisation admis-
sions or intravenous antibiotics <2 weeks before signing the informed consent, changes in the
usual treatment (prokinetics, proton pump inhibitors, H2 blockers and antibiotics) <2 weeks
before signing the informed consent, presence of other alterations that would potentially
endanger the safety of the patient as estimated by the researchers (for example other drugs,
newly diagnosed CF-related diabetes, etc.) and hypersensitivity or adverse reactions to the
enzymatic supplements. Lung transplantation was considered an exclusion criterion too.
Study design
We carried out a multicentre, prospective, interventional pilot study. All the patients followed
a fixed, predefined study diet composed by the previously in vitro digested foods, in combina-
tion with a fixed predefined dose of enzymatic supplements used in PERT based on the TOD
obtained in the in vitro digestion studies (Fig 1). The enzymatic supplements consisted of
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enteric-coated microspheres of porcine-origin pancreatin, including amylase, protease and
mainly lipase.
Patients were provided with the study protocol, which included a detailed instruction hand-
book to perform the study and as a weighted food record. Structured as a 3-day diary, the
study protocol showed pictograms with the exact amount of each food item to be registered by
the patient or the caregiver and the corresponding dose of enzymes for each meal. When a
higher or a lower amount of the indicated portion for each food was taken, the patient had to
indicate it, but the indicated dose of the enzymatic supplement was maintained. Also questions
about adherence to PERT and test diet were asked. The only extra foods permitted between
test meals were fat-free food, such as fruit or jelly, which did not require the intake of enzy-
matic supplement. The researchers provided a pillbox with different compartments containing
the predefined TOD of the enzymatic supplement labelled for each test meal. When TODs
were in between the regular capsule sizes, half of the content of a capsule was emptied in order
to meet the recommended LU. A form was asked to be filled at the end of each day reporting
the number of bowel movements, deposition time, colour and Bristol stool score. Patients
were asked to collect faeces corresponding to the ingestion of the study menu: this was made
possible by using colorimetric markers at the start and at the end of the study diet. The colori-
metric markers (blue and red) were also included in the pillbox given to the participants.
At the study visit, patients’ individual characteristics were collected as study variables: age, gen-
der, intake of proton pump inhibitor, BMI z-score, and CFTR mutations, defined as Class I, Class
II and Class III [15]. The study protocol was approved by the ethical committee of each centre:
Fig 1. Overview of the combined in vitro and in vivo approach to validate a new evidence-based predictive model to optimally adjust the dose of
enzymatic supplements used in PERT, adapted to food and patient characteristics. First a selection of 8 meals were digested in vitro under standard CF
conditions, and the % of lipolysis was obtained for the different doses of the enzymatic supplement. Modelling of the % lipolysis extent allowed predicting the
theoretical optimal dose for each meal (TOD), which took into account the food characteristics. Second, in the in vivo study the same 8 meals were digested in
vivo under real conditions along with their TODs, and the % of fat absorption was measured in all the participating patients. Modelling of the coefficient of fat
absorption (CFA) allowed to obtain how different TOD should have been in order to achieve a 90% of CFA (the equivalent outcome to the in vitro setting). In
authors’ criterion, the individual correction factor (ICF) allowed for quantifying the relation between the in vitro and the in vivo settings. TOD, theoretical
optimal dose; IOD, individual optimal dose; ICF, individual correction factor.
https://doi.org/10.1371/journal.pone.0213216.g001
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Hospital Universitari i Politècnic La Fe (Valencia), Hospital Universitario Ramo´n y Cajal
(Madrid), Ospedale Maggiore Policlinico (Milan), Universitair Ziekenhuis Leuven Hospital (Leu-
ven) and Erasmus MC Sophia’s Children Hospital (Rotterdam). All parents and patients were
informed about the purpose and ultimate aim of the study and gave written informed consent.
The test diet and study doses. The study period included a test diet composed by 6 meals
distributed in 24 hours, and also a washout diet period before and after the test diet itself (3
meals) to minimise the impact of the regular and uncontrolled normal diets of the participants
in the faecal analysis. All the meals included in the test diet had been previously digested in
vitro and the corresponding TODs were estimated considering the most unfavourable intesti-
nal conditions of pH 6 and bile salts concentration of 1 mM according to previous literature
[16–18]. Fig 2 provides the overview of the study timeline per patient.
In the design of the meals the following considerations were taken into account for the fea-
sibility and to avoid country-related potential bias: meals had to fit all the nutritional habits
according to previous results of our group [19], international brands had to be used in order to
achieve the same nutritional composition and easy cooking techniques were to be used, so that
the assumption that the TOD was maintained in the foods used in all the countries could be
made. To calculate the nutrient profile of the test meals, the nutritional composition databases
of EuroFIR and Nubel were upgraded including the nutrient information directly from the
specific test food labelling. Four energy levels were proposed so that patients of all ages could
participate: 1622, 1832, 2194 and 2573 kcal/24h. In all of them, the macronutrient distribution
was approximately 40% lipids, 40% carbohydrates and 20% protein, according to the nutrition
guidelines [1]. In each level, the foods were the same, but the amount varied and TOD dose
was adapted proportionally (Table 1). Therefore, the dose of the enzymatic supplement in LU/
g of fat was the same for all the participants, regardless the amount of food they had. Families
and patients were allowed to choose the level of energy together with the dietitian that most
appropriately fitted the appetite and habits of the participant. Participants were strictly
instructed by the investigators to purchase the indicated brands for each product.
Fig 2. Overview of the study. The study started at day 1 afternoon with a washout diet including a fixed dose of the enzymatic supplement (TOD) (snack 2)
and the administration of the red marker. From then on, and during day 2 patients followed the test diet with the fixed dose of the enzymatic supplement
(TOD), until the afternoon snack on day 2, that was taken in combination with the blue markers. The dinner of day 2 and the breakfast of day 3 conformed the
washout diet after the test menu, also with a fixed dose of the enzymatic supplement (TOD). Faecal samples had to be collected from the moment of the red
colour intake until the first blue-dyed deposition was found. For the faecal analysis, researchers selected the samples comprised from the 1st red deposition to
the 1st blue. WO, washout.
https://doi.org/10.1371/journal.pone.0213216.g002
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Faecal collection and analysis. Detailed instructions were given to minimise the error in
the CFA calculations. From the moment of the red marker intake, all the faeces had to be col-
lected individually into separate plastic bags. Fecotainers (AT Medical BV, The Netherlands)
were provided to the patients to ease the collection. This process was repeated until the blue
colour was identified in the faeces.
The faeces were shipped from all the participating centres to Instituto de Investigacio´n
Sanitaria La Fe (Valencia, Spain) for central analysis. Homogenisation of all samples from each
patient was carefully carried out, including only the faeces corresponding to the test menu: the
samples that were collected before the appearance of red-dyed faeces were discarded. Samples
considered for the analysis comprised those collected between the 1st red and the 1st blue-
Table 1. Theoretical optimal doses of enzymatic supplement (TOD) expressed in lipase units per gram of fat (LU/g fat) for a selection of eight foods previously
determined by means of an in vitro digestion model. Combination of the foods conformed the meals used in the study protocol in order to assess the efficacy of the
TOD assigned to each food.
Test meal Fat content (g/
100g)
Theoretical optimal dose of enzymes
(TOD) (LU/ g fat)
Portion size (g) per test diet
level (La)
Fixed dose of enzymatic supplement based on
TOD (total LU)
Salad with olive oil 10 1613 L1: 70 11291
L2: 100 16130
L3: 100 16130
L4: 150 24195
Ham & cheese
Pizza
8.3 1375 L1: 170 19401
L2: 220 25107
L3: 220 25107
L4: 250 28531
Yoghurt 10 1240 L1: 125 15500
L2: 125 15500
L3: 125 15500
L4: 125 15500
Ham & cheese
Sandwich
10.2 1660 L1: 110 18625
L2: 130 22011
L3: 140 23704
L4: 140 23704
Milk 3.6 1480 L1: 200 10656
L2: 200 10656
L3: 250 13320
L4: 250 13320
Buttery bread 28.3 3400 L1: 40 38488
L2: 40 38488
L3: 40 38488
L4: 40 38488
Cereal 4 4720 L1: 30 5664
L2: 30 5664
L3: 50 9440
L4: 50 9440
Biscuit 25.9 6130 L1: 11 17464
L2: 22 34928
L3: 33 52293
L4: 44 69857
a L1, level of energy 1, 1622 kcal/24h; L2, level of energy 2, 1832 kcal/24h; L3, level of energy 3, 2194 kcal/24h; L4, level of energy 4, 2573 kcal/24h
https://doi.org/10.1371/journal.pone.0213216.t001
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dyed, both included. Therefore, the quantification of fat in faeces considered for the CFA cal-
culation was as accurate as possible, given that only fat corresponding to the test diet was con-
sidered. Then household stirrers 750 W were used to mix the faeces contained in the original
recipients until complete homogenisation was observed (5 minutes per sample approx.,
depending on the consistency and volume). This faecal homogenisation method was chosen
because of the lack of a standardised method in the literature. Previous studies focused on fae-
cal analyses did not describe the protocol for homogenisation in detail, or did not make it
available [20–23].
Careful cleaning of the equipment was performed between samples. Then the homogenised
sample was aliquoted in 10 g recipients and kept under freezing conditions (-20˚C).
Quantitative faecal fat analyses were carried out by the infrared spectroscopy technique, the
gold standard to perform fat in faeces analyses at the Reference Laboratory (Barcelona, Spain).
Random selected samples (n = 10) were used to assess the homogenisation protocol developed.
Test results were highly reproducible (CV<15%) between two different aliquots of the same
homogenised sample.
The CFA was calculated as the percentage of fat excreted in faeces (considering the faeces
belonging to the test diet) compared to the fat in the test diet. This parameter is considered
equivalent to the % lipolysis extent used in the in vitro setting. The transit time was calculated
as the time between the ingestion of the red capsule and the moment the first red faeces
appeared, despite the fact that this method of calculation may have only allowed for an esti-
mated result.
The Bristol Stool Scale was used for patients to report the faecal consistency [24]. This scale
is used to assess gastrointestinal complications, and ranges from 1 to 7, where 1 is extreme con-
stipation and 7 extreme diarrhoea, and the optimal types are 3–4.
Calculations and statistical analyses
Sample size calculation was performed assuming that differences in undigested fat between in-
vitro and in-vivo digestions would range between 0 g and 18 g, with a mean value of 9 g and a
standard deviation of 3 g (according to a retrospective review of clinical data from patients
from one of the participating centres [7]). With these values, 41 individuals would be needed
to achieve a precision of ±1 g of fat (95% CI length of 2) in the determination of the differences
in undigested fat between in-vitro and in-vivo values. Assuming a drop-out of 20% of the
recruited patients, the sample size was estimated to be 50 subjects.
For the descriptive analysis, data were summarised using mean (standard deviation) or
median (1st, 3rd Q.) in the case of continuous variables and with relative and absolute frequen-
cies in the case of categorical variables.
A beta regression model was applied to study the association between the CFA and the
selected study variables: age, dose of the enzymatic supplement (i.e. TOD), use of proton
pump inhibitor (PPI) and transit time.
The results of the beta regression model can be interpreted with the exp(estimate) and the
CI 95%. An exp(estimate) >1 means that the variable is positively associated with the response
variable and the higher the value, the higher the effect. Complementarily, the confidence inter-
vals that do not contain 1 are those significantly associated with the response variable.
This model was applied to calculate the optimal dose of enzymes for each patient (individ-
ual optimal dose, IOD) to reach a target of 90% lipolysis extent (i.e., CFA), according to the
individual patient characteristics by means of the equation of the model (Eq 1).
gð%CFAÞ ¼ b0 þ ðb1 � transit timeÞ þ ðb2 � IODÞ þ ðb3 � ageÞ þ ðb4 � PPI intakeÞ ð1Þ
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where g (�) is the logit function of the beta regression, IOD is the individual optimal dose of
enzymes and PPI is proton pump inhibitors. βi,i = 0,. . .,4 are the model parameters.
Therefore, to calculate the individual optimal dose (IOD) for each patient to reach the clini-
cal target of 90% CFA, this equation should be solved (Eq 2):
IOD ¼
gð90%clinical target CFAÞ   b0   ðb1 � transit timeÞ   ðb3 � ageÞ   ðb4 � PPI intakeÞ
b2
ð2Þ
Then, the relationship between the individual dose of enzymes and the actual TOD taken
by the patient in the study conformed the individual correction factor. The individual correc-
tion factor is thus the ratio that reflects the relationship between the in vitro and the in vivo set-
tings of the digestion (Eq 3). This ratio, thus, expresses how different the TOD has to be, either
higher or lower, than the one predicted in vitro, encompassing the individual characteristics
that differ from those standard characteristics simulated in vitro.
ICF ¼
IOD
TOD
ð3Þ
Where ICF is the individual correction factor; IOD is the in vivo optimal dose obtained by Eq
1 in which patients characteristics were considered, in order to reach a 90% of CFA; and TOD
is the theoretical optimal dose of enzymes obtained in vitro, which was actually taken by the
participants during the study.
A mixed ordinal regression model was carried out to study the association between CFA
and the response Bristol Stool Scale due to the ordinal nature of the response (type 1 trough 7,
not a continuous scale). Furthermore, because the faeces samples from the same patient are
more likely to have a similar Bristol Stool Scale number than those from other patients, the
model was extended with the "Patient" variable as a random effect with a random intercept to
correct for the non-independence of the data.
Patients’ compliance with the study protocol was defined as intake of fat and dose of enzy-
matic supplement as compared to the indicated amount (%).
All the analyses were performed using R software (version 3.3.3), and lme4 (version 1.1–
12), nlme (version 3.1–131), ordinal (version 2016.6–28), betareg (version 3.1–0), clickR (ver-
sion 0.3.35) packages. A p-value below 0.05 was considered statistically significant.
Results
A total of 54 patients were enrolled in the study between April and June 2017: 9 from Madrid,
12 from Valencia, 5 from Milan, 13 from Leuven and 9 from Rotterdam. Eleven participants
dropped out due to stress for defecating in bags (n = 5), because of severe infections that were
not related to the study (n = 2) and antibiotic use (n = 2), so the final number of participants
was 43.
Patients characteristics and descriptive results
Table 2 shows the patient characteristics of the study population and the descriptive results of
the pilot study. Median age, BMI z-score and transit time were 9.4 years, -0.02 SD and 28.5h
respectively. The median dose of enzymatic supplement was around 2599 LU/g fat, according
to the indications in the protocol for the participants. Compliance with the test diet and the
test dose of enzymatic supplement (TOD) were 98.4 and 100% respectively. None of the col-
lected variables presented statistical differences among centres. None of the recruited patients
reported adverse events related to the study nor symptoms or complaints with the exception of
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one patient who experienced an episode of acute diarrhoea. None of the patients were taking
laxatives at the time of the study nor had previous gut resection.
The coefficient of fat absorption CFA. Overall, median CFA value was 90.0% and analy-
sis of data for individual centre revealed the same distribution of CFA values. When analysing
results of each centre individually the same distribution was found in all (Fig 3), which ranged
from 83.7% (1st quartile) to 94.4% (3rd quartile) and no significant differences in CFA between
centres (p = 0.60). There were three outliers: one in Madrid (CFA 53%) due to the inaccurate
faecal collection; and two in Leuven, one developed diarrhoea with reported Bristol stool scale
of 7 and transit time of 12 h (CFA 61%) and the other due to the low adherence the protocol
(CFA 68%).
Bristol Stool Scale and CFA. Most of the faecal samples were identified by the partici-
pants as Bristol stool scale types 3 and 4 (normal) and 2 (constipation) as shown in Fig 4. No
association was found between CFA and Bristol Stool Scale number (p>0.05).
A beta regression model to predict the individual correction factor
Table 3 shows the parameters of the beta regression model including the variables that were
selected. The variables type of CFTR mutations and BMI z-score were not included in the
model as mutations were severe in all the patients and the BMI z-score did not show any effect
in alternative models explored previously. As for the selected variables, the CFA was signifi-
cantly associated with the transit time (p = 0.007): the longer the transit time, the higher the
CFA (CI 95% [1.177, 2.797]). The CFA was not significantly associated with PPI intake, TOD
and age (p = 0.09, p = 0.14 and p = 0.62 respectively).
The resulting equation (Eq 4) of the beta regression model was applied to predict the indi-
vidual optimal dose of enzymatic supplement, which is what the dose should have been in
order to achieve a 90% CFA instead of the CFA value actually obtained with the TOD. This
Table 2. Patients’ characteristics and results of the pilot study in which an in vitro digestion method was set-up to assess the optimal dose of pancreatic enzyme
replacement therapy according to food characteristics.
Madrid
(n = 9)
Valencia
(n = 10)
Milan
(n = 5)
Leuven
(n = 12)
Rotterdam
(n = 7)
Total
(n = 43)
Age (years)
Median (1st, 3rd Q.)
12.1
(9.3,14.5)
7.5
(6.9,16.3)
8.2
(6.2,11.6)
7.4
(7.2, 8.5)
10.1
(9.6, 12.9)
9.4
(6.8, 13.8)
Male, n (%) 6 (67) 5 (50) 2 (40) 7 (58.3) 3 (43) 23 (55)
BMI z-score
Median (1st, 3rd Q.)
0.01
(-0.08, 0.07)
-0.24
(-1, 0.41)
-0.26
(-0.94, 0.58)
0.08
(-0.5, 0.3)
-0.02
(-0.2, 0.66)
-0.02
(-0.64, 0.42)
CFA (%)
Median (1st, 3rd Q.)
91.2
(84.7, 93.9)
88.8
(84.9, 92.8)
94.1
(84.7, 95.2)
88.1 (79.7,91.47) 89.9
(87.5, 94.3)
90.0
(83.7, 94.4)
Total fat in faeces (g)
Median (1st, 3rd Q.)
7.8
(6.7, 9.5)
8.1
(4.85, 10.62)
5.9
(3.5, 9.6)
10.35
(7.2, 15.8)
9.45
(5.1, 11.1)
8.4
(4.8, 12.3)
Transit time (h)
Mean (SD)
24.2
(15.1)
25.9
(12.9)
30.4
(19.2)
30.0
(10.7)
32.1
(13.2)
28.5
(15.1)
Proton Pump Inhibitors (PPI), n (%) 3
(33.3)
4
(40)
1
(20)
4
(33.3)
2
(28.6)
14
(33)
TOD (LU/g fat)
Median (1st, 3rd Q.)
2271
(2243, 2540)
2802
(2315, 2866)
2509
(2000, 2579)
2706
(2557, 2786)
2624
(2602, 2977)
2599
(2310, 2817)
Compliance with test diet (%)
Median (1st, 3rd Q.)
108.7
(97.0, 112.2)
94.7
(87.0, 105.5)
99.9
(93.2, 100.0)
100.1
(92.5, 106.4)
97.0
(88.8, 105.3)
98.4
(92.5, 108.3)
Compliance TOD (%)
Median (1st, 3rd Q.)
100
(89.4, 100)
94.11
(84.7, 100)
85.5
(62.7, 100)
100
(100, 103.4)
100
(94.4, 100)
100
(92.5, 100)
Compliance exceeding 100% means that amount of fat or enzymes was higher than the indicated in the protocol
https://doi.org/10.1371/journal.pone.0213216.t002
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change would have been determined by the individual patient characteristics (transit time, age
and PPI intake).
gð%CFAÞ ¼ 1:043þ ð0:596 � transit timeÞ   ð0:0004 � IODÞ þ ð0:013 � ageÞ þ ð0:312
� PPI intakeÞ ð4Þ
where g (�) is the logit function of the beta regression, IOD is the individual optimal dose of
enzymes and PPI is proton pump inhibitors.
Then Eq 3 was applied in order to determine the relationship between the TOD and the indi-
vidual dose of enzymes, or the relationship between the in vitro and the in vivo setting. This
relationship would have conformed the individual correction factor. The individual correction
factor median was found to be 0.95 (0.92, 1.01) in all the cases, meaning that optimal dose
obtained in vitro (TOD) was equivalent to the required dose in vivo (individual optimal dose).
Discussion
Through the present study we have moved from an in vitro experimental set-up to an in vivo
setting to evaluate the model for adjusting the dose of enzymatic supplements used in PERT in
CF. The in vitro digestion study allowed for the estimation of a TOD of the enzymatic supple-
ment for different meals and foods, and in this pilot study we have assessed the validity of this
Fig 3. Results of the coefficient of fat absorption (CFA) obtained in the participating centres. The horizontal dotted bar represents the median CFA of the total
population, coinciding with the clinical target of 90%. Boxplots represent the median and the 1st and 3rd quartiles in all the centres.
https://doi.org/10.1371/journal.pone.0213216.g003
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approach. We had hypothesised that when applying the TOD in vivo, specific individual cor-
rections would be needed based on the individual subject’s characteristics. However, we found
that these characteristics did not imply a modification of the dose predicted in the lab, being
the relationship between both settings close to 1. In other words, our results suggest that the
food characteristics are the determinants of the requirements of enzymatic supplement, and
not the individual patient characteristics we have assessed.
In our clinical setting, using the TOD of enzymatic supplements, the median CFA was
found to be 90%, which is slightly higher than in previous studies, and comparable to others
Fig 4. Representation of number of faecal depositions per patient and centre and the Bristol stool scale type assigned to each individual deposition by
the patient or caregiver (one patient per row). Faecal samples correspond to the study period, from the red to the blue coloured deposition.
https://doi.org/10.1371/journal.pone.0213216.g004
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without predefined dose [8,9]. In a similar CF-population from Valencia a mean CFA of 86%
was reported [9]. In that study a high variability between patients, and within patients (differ-
ences in CFA in 3 consecutive days) along 3 visits in a year was found and attributed to the
uncontrolled diet and dose of enzymes for the specific meals [9]. In contrast, in the present
study with a controlled diet, we found a lower between-patients variability (84 to 94% 1st, 3rd
Q.), which suggests that the TOD had similar responses in all the participants. This is con-
firmed by the fact that most of the faeces were scored types 3–4 on the Bristol stool scale,
which indicate the absence of gastrointestinal complications, including persistent diarrhoea
and malabsorption. In addition, the patients reported no symptoms or complications so there
were no gastrointestinal alterations during the study period.
With regard to the multivariate model, the equation derived from the selected parameters
was supposed to be used to calculate the individual optimal dose. With the equation of the
model, according to the parameters and the individual characteristics of the patients, such as
age and PPIs intake, the optimal LU/g fat (individual optimal dose of enzymes) could be calcu-
lated in order to obtain the desired CFA of 90%. However, these characteristics turned out to
have a very low overall effect, so the TOD and the individual optimal dose of enzymes were
almost the same in all the cases (i.e. the individual correction factor was around 1 for all the
patients). The positive (but not significant) effect of proton pump inhibitors has been repeat-
edly reported in patients with CF [25,26]. The rationale behind it is that PPI’s inhibits the acid
secretion in the stomach and thus higher pH values are achieved for the intestinal digestion
phase. Lipase activity is directly associated with the intestinal pH [27]. This phenomenon was
clearly observed previously [15].
There are several limitations in this study. First, performing the test at home may have
caused deviations from the protocol, which implied high complexity to the patients. However,
in order to minimise complications, a thoughtful protocol for the participant was given in
which detailed information about the type of foods and brands was specified. In addition, a
questionnaire after each meal was included and finally a depositions registry had to be filled in
to assess the degree of adherence, which was found to be nearly 100% despite the potential
risks for deviations. Second, the number of variables included in the statistical model were lim-
ited due to the low patient number. In addition, the model relies on non-significant associa-
tions, thus its validity as a predictive model to calculate the individual correction factor in
every patient is limited. Nonetheless, according to the statistical results, if more patients had
been included, the same results distribution of results was to be expected as long as the proto-
col was strictly followed. Hence, the multivariate model would not have allowed for an individ-
ual optimal dose prediction either. Other potentially interesting variables representing
patients’ individual characteristics that could have provided clearer explanation of the results
could be intestinal pH and bile salts concentration, but because of the complexity and invasive-
ness of the methods to collect this information, we did not include these variables in the frame-
work of the study. We indeed acknowledge that in the patients with the lower CFA results, a
Table 3. Beta regression model to assess the influence of the study variables on CFA, including the dose of
enzymes (TOD) and the individual factors intake of proton pump inhibitors (PPI), age and transit time.
(exp)Estimate Confidence Interval CI 95% p-value
(Intercept) (β0) 2.839 [0.223, 36.147] 0.42
TOD (β2) 0.999 [0.998, 1.000] 0.13
PPI intake (β4) 1.367 [0.885, 2.115] 0.09
Age (β3) 1.013 [0.961, 1.069] 0.62
Transit time (β1) 1.815 [1.177, 2.797] 0.007
https://doi.org/10.1371/journal.pone.0213216.t003
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lower than 6 intestinal pH could be the reason for that finding. However, most of the patients
had a high CFA value, and was probably the main reason for no statistical association of CFA
and other study variables (apart from transit time). Another limitation is that the present study
design relied on the results generated by an in vitro digestion model simulating CF gastrointes-
tinal digestion. Finally, despite some assumptions or simplifications were made in this model,
the CFA results obtained suggests that the real and more complex physiological conditions of
in vivo digestion (for example, possible higher pH or bile salts concentration or residual pan-
creatic function) may have contributed to compensate for these possible limitations.
In contrast, the strengths of the present study rely on the robust methodology. To our
knowledge, there are no studies assessing the dose of the enzymatic supplement and CFA in
the context of such an accurate and detailed protocol for faecal collection, homogenisation of
faeces samples, analysis and CFA calculation. In our study for the first time CFA was estimated
while on a fixed diet and a fixed dose of enzymes, and in addition using an evidence-based
approach.
Overall, when strictly following the protocol (including test menu, TODs and faecal collec-
tion) and in the absence of adverse events interfering with fat digestion and/or absorption,
TODs were precise enough to obtain good CFA values and no other patient-related factors
with a relevant influence on the individual correction factor could be postulated.
Our findings may open a new perspective on the treatment of pancreatic insufficiency in
CF. Currently patients with CF have to decide the dose of enzymatic supplement to take every
single time they eat. As a matter of fact, large differences in dosing criteria were previously
documented between European countries, evidencing the lack of a common consensus [10].
The newly developed evidence-based method to adjust PERT could be implemented in the
clinical practice to support clinicians and patients’ decision on the dose of the enzymatic sup-
plement, possibly contributing to a more efficient nutrient digestion and absorption, and con-
sequently, to a better nutritional status.
We showed that the digestion of fat is more dependent on the food characteristics than on
the patient characteristics. Ideally, a dose tailored at each single meal could be foreseen. For
this implementation, however, a supporting system would be required. In MyCyFAPP project,
we have developed a mobile app including a calculation algorithm of the optimal dose of enzy-
matic supplements based on a database of TODs. The next step of MyCyFAPP project will
assess the effects of using this app on health and quality of life-related outcomes. However,
before moving to a larger study cohort for validation, this pilot study was necessary prerequi-
site. The results obtained seem to indicate this pilot study suggests further research in this
innovative approach.
In conclusion, we have made a step ahead in the understanding of PERT dosing and we
have set up the first evidence-based method to adjust the dose of the enzymatic supplement to
food characteristics in CF. Although we expected that optimal dosing of the dose would be
based not only on the theoretical optimal dose obtained in vitro but also by adding an individ-
ual correction factor related to the characteristics of each patient, this could not be defined.
Since the in vitro predicted TODs led to the clinical target CFA results in vivo, it can be reliably
used as a first approach towards further research. We should evaluate the effect on nutritional
outcome as well as the overall lung function in future.
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